Erasca, Inc. – NASDAQ:ERAS
Founder-led company
Erasca stock price today
$1.54
-1
-39.37%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 6 hours
Erasca stock price monthly change
-14.48%
month
Erasca stock price quarterly change
-14.48%
quarter
Erasca stock price yearly change
+18.14%
year
Erasca key metrics
Market Cap | 696.92M |
Enterprise value | 119.87M |
P/E | -1.42 |
EV/Sales | N/A |
EV/EBITDA | -0.38 |
Price/Sales | N/A |
Price/Book | 0.84 |
PEG ratio | 0.18 |
EPS | -0.84 |
Revenue | N/A |
EBITDA | -140.45M |
Income | -126.86M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeErasca stock price history
Erasca stock forecast
Erasca financial statements
Average Price Target
$6
Potential upside: 289.61%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -31.78M | |
|---|---|---|---|
| Sep 2023 | 0 | -30.36M | |
| Dec 2023 | 5.58M | -29.70M | -532.28% |
| Mar 2024 | 0 | -35.01M |
| 2022-11-09 | -0.31 | -0.29 |
|---|---|---|
| 2023-03-23 | -0.32 | -1.06 |
| 2023-05-11 | -0.3 | -0.31 |
| Jun 2023 | 440662000 | 77.95M | 17.69% |
|---|---|---|---|
| Sep 2023 | 419406000 | 80.43M | 19.18% |
| Dec 2023 | 395297000 | 78.61M | 19.89% |
| Mar 2024 | 370022000 | 81.61M | 22.06% |
| Jun 2023 | -25.95M | -108.66M | 649K |
|---|---|---|---|
| Sep 2023 | -24.12M | -1.81M | 7K |
| Dec 2023 | -24.78M | 4.54M | 456K |
| Mar 2024 | -33.25M | 9.97M | 6.93M |
Erasca alternative data
| Aug 2023 | 129 |
|---|---|
| Sep 2023 | 129 |
| Oct 2023 | 129 |
| Nov 2023 | 129 |
| Dec 2023 | 129 |
| Jan 2024 | 129 |
| Feb 2024 | 129 |
| Mar 2024 | 129 |
| Apr 2024 | 129 |
| May 2024 | 126 |
| Jun 2024 | 126 |
| Jul 2024 | 126 |
Erasca other data
16.87%
-49.17%
of ERAS is owned by hedge funds
63
-42
20.58M
-59.19M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 100000 | 0 |
| Oct 2023 | 1000000 | 0 |
| Dec 2023 | 1040000 | 0 |
| May 2024 | 80000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | CASDIN ALEXANDER W. director | Common Stock | 80,000 | $2.27 | $181,920 | ||
Purchase | START VALERIE DENISE HARDING director | Common Stock | 10,000 | $1.85 | $18,480 | ||
Purchase | LIM JONATHAN E director, 10 perc.. | Common Stock | 278,150 | $1.72 | $478,418 | ||
Purchase | LIM JONATHAN E director, 10 perc.. | Common Stock | 721,850 | $1.69 | $1,217,761 | ||
Purchase | CASDIN ALEXANDER W. director | Common Stock | 30,000 | $1.66 | $49,800 | ||
Purchase | LIM JONATHAN E director, 10 perc.. | Common Stock | 1,000,000 | $2.03 | $2,026,000 | ||
Purchase | LIM JONATHAN E director, 10 perc.. | Common Stock | 100,000 | $2.75 | $275,000 | ||
Purchase | CASDIN ALEXANDER W. director | Common Stock | 20,000 | $2.76 | $55,240 | ||
Purchase | LIM JONATHAN E director, 10 perc.. | Common Stock | 100,000 | $2.84 | $284,000 | ||
Purchase | LIM JONATHAN E director, 10 perc.. | Common Stock | 60,000 | $3.86 | $231,420 |
| Quarter | Transcript |
|---|---|
| Q4 2023 29 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Jonathan E. Lim (1972) Co-Founder, Chairman & Chief Executive Officer | $480,000 |
Dr. David M. Chacko M.D. (1983) Chief Financial Officer | $455,300 |
Dr. Michael D. Varney Ph.D. (1958) Chairman of R&D, Scientific Advisory Board member and Director | $26,300 |
Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge
August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February
Erasca: Potential Strong Upside Ahead
MDA Breakout Stocks Week 6 - February 2023: High-Frequency Gainers To Give You An Edge
-
What's the price of Erasca stock today?
One share of Erasca stock can currently be purchased for approximately $1.54.
-
When is Erasca's next earnings date?
Unfortunately, Erasca's (ERAS) next earnings date is currently unknown.
-
Does Erasca pay dividends?
No, Erasca does not pay dividends.
-
How much money does Erasca make?
Erasca has a market capitalization of 696.92M. Erasca made a loss 125.04M US dollars in net income (profit) last year or -$0.31 on an earnings per share basis.
-
What is Erasca's stock symbol?
Erasca, Inc. is traded on the NASDAQ under the ticker symbol "ERAS".
-
What is Erasca's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Erasca?
Shares of Erasca can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Erasca's key executives?
Erasca's management team includes the following people:
- Dr. Jonathan E. Lim Co-Founder, Chairman & Chief Executive Officer(age: 53, pay: $480,000)
- Dr. David M. Chacko M.D. Chief Financial Officer(age: 42, pay: $455,300)
- Dr. Michael D. Varney Ph.D. Chairman of R&D, Scientific Advisory Board member and Director(age: 67, pay: $26,300)
-
Is Erasca founder-led company?
Yes, Erasca is a company led by its founder Dr. Jonathan E. Lim.
-
How many employees does Erasca have?
As Jul 2024, Erasca employs 126 workers, which is 2% less then previous quarter.
-
When Erasca went public?
Erasca, Inc. is publicly traded company for more then 4 years since IPO on 16 Jul 2021.
-
What is Erasca's official website?
The official website for Erasca is erasca.com.
-
Where are Erasca's headquarters?
Erasca is headquartered at 10835 Road to the Cure, San Diego, CA.
-
How can i contact Erasca?
Erasca's mailing address is 10835 Road to the Cure, San Diego, CA and company can be reached via phone at 858 465 6511.
-
What is Erasca stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Erasca in the last 12 months, the avarage price target is $6. The average price target represents a 289.61% change from the last price of $1.54.
Erasca company profile:
Erasca, Inc.
erasca.comExchange:
NASDAQ
Full time employees:
126
Industry:
Biotechnology
Sector:
Healthcare
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
10835 Road to the Cure
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001761918
ISIN: US29479A1088
CUSIP: 29479A108
